PMID- 37016490
OWN - NLM
STAT- MEDLINE
DCOM- 20230509
LR  - 20230530
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 38
IP  - 2
DP  - 2023 Apr
TI  - Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean 
      Adults: A Nationwide Matched Cohort Study.
PG  - 245-252
LID - 10.3803/EnM.2023.1662 [doi]
AB  - BACKGRUOUND: Coronavirus disease 2019 (COVID-19) can cause various extrapulmonary 
      sequelae, including diabetes. However, it is unclear whether these effects 
      persist 30 days after diagnosis. Hence, we investigated the incidence of newly 
      diagnosed type 2 diabetes mellitus (T2DM) in the post-acute phase of COVID-19. 
      METHODS: This cohort study used data from the Health Insurance Review and 
      Assessment Service, a representative national healthcare database in Korea. We 
      established a cohort of 348,180 individuals diagnosed with COVID-19 without a 
      history of diabetes between January 2020 and September 2021. The control group 
      consisted of sex- and age-matched individuals with neither a history of diabetes 
      nor COVID-19. We assessed the hazard ratios (HR) of newly diagnosed T2DM patients 
      with COVID-19 compared to controls, adjusted for age, sex, and the presence of 
      hypertension and dyslipidemia. RESULTS: In the post-acute phase, patients with 
      COVID-19 had an increased risk of newly diagnosed T2DM compared to those without 
      COVID-19 (adjusted HR, 1.30; 95% confidence interval [CI], 1.27 to 1.33). The 
      adjusted HRs of non-hospitalized, hospitalized, and intensive care unit-admitted 
      patients were 1.14 (95% CI, 1.08 to 1.19), 1.34 (95% CI, 1.30 to 1.38), and 1.78 
      (95% CI, 1.59 to 1.99), respectively. The risk of T2DM in patients who were not 
      administered glucocorticoids also increased (adjusted HR, 1.29; 95% CI, 1.25 to 
      1.32). CONCLUSION: COVID-19 may increase the risk of developing T2DM beyond the 
      acute period. The higher the severity of COVID-19 in the acute phase, the higher 
      the risk of newly diagnosed T2DM. Therefore, T2DM should be included as a 
      component of managing long-term COVID-19.
FAU - Choi, Jong Han
AU  - Choi JH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk 
      University School of Medicine, Seoul, Korea.
FAU - Kim, Kyoung Min
AU  - Kim KM
AD  - Division of Endocrinology, Department of Internal Medicine, Yongin Severance 
      Hospital, Yonsei University College of Medicine, Yongin, Korea.
FAU - Song, Keeho
AU  - Song K
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk 
      University School of Medicine, Seoul, Korea.
FAU - Seo, Gi Hyeon
AU  - Seo GH
AD  - Health Insurance Review and Assessment Service, Wonju, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230405
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
SB  - IM
MH  - Humans
MH  - Adult
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology/diagnosis
MH  - *COVID-19/epidemiology/complications
MH  - Incidence
MH  - Republic of Korea/epidemiology
PMC - PMC10164491
OTO - NOTNLM
OT  - COVID-19
OT  - Diabetes mellitus, type 2
OT  - Post-acute COVID-19 syndrome
OT  - SARS-CoV-2
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2023/04/06 06:00
MHDA- 2023/05/09 06:42
PMCR- 2023/04/01
CRDT- 2023/04/05 00:13
PHST- 2023/01/14 00:00 [received]
PHST- 2023/03/24 00:00 [accepted]
PHST- 2023/05/09 06:42 [medline]
PHST- 2023/04/06 06:00 [pubmed]
PHST- 2023/04/05 00:13 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - EnM.2023.1662 [pii]
AID - enm-2023-1662 [pii]
AID - 10.3803/EnM.2023.1662 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2023 Apr;38(2):245-252. doi: 10.3803/EnM.2023.1662. 
      Epub 2023 Apr 5.